Over the past 30 years, I have focused my clinical research in expanding our understanding of the immunobiology of human cancer and the development of new immune therapies. Our NCI funded clinical trials were aimed at minimizing regulatory and suppressive pathways and enhancing existent tumor-specific immune function.
I did my cancer immunology and immunotherapy training with John M. Kirkwood while at Yale University. I continued to develop my experience and qualifications as a translational immunotherapy clinical scientist while at Yale and the University of Pittsburgh and Pittsburgh Cancer Institute. I was a cadre member of the both CALGB and ECOG melanoma programs and am currently a member of the Alliance Experimental Therapeutics Program.
I am currently the Geisel PI on the Cancer Immunotherapy Trial Network and on the executive council of the Cytokine Working Group. I have published over 200 original research manuscripts in the areas of renal cell cancer, melanoma and immune therapy strategies including cytokine therapies, dendritic cell vaccines, immune checkpoint inhibition, targeted therapies and ex vivo expanded effector cells for adoptive transfer. My laboratory has developed phenotypic, functional and molecular assays which enable us to explore the immune response to disease and therapy. While at the University of Pittsburgh and the Pittsburgh Cancer Institute, I was the Director of the Hematology/Oncology Fellowship Program and PI on a T32 Training award from the NCI.
Over the years, I have successfully mentored five medical students, ten residents, 39 postdoctoral/fellows, and 18 junior faculty. I was Staff Physician at the Taussig Cancer Institute, Cleveland Clinic Foundation and Director of the Melanoma Program and Professor in the Cleveland Clinic Lerner School of Medicine. In 2016, I assumed the role of Professor and Chair, Department of Medicine, Senior Vice President for Clinical Investigation, The Katherine Anne Gioia Chair of Medicine, Roswell Park Cancer Institute and Professor and Chief of the Section of Oncology at the University of Buffalo.
• Immunobiology of human cancer and the development of new immune therapies
• Renal cell cancer, melanoma and immune therapy strategies; including cytokine therapies, dendritic cell vaccines, immune checkpoint inhibition, targeted therapies and ex vivo expanded effector cells for adoptive transfer
• Exploring the immune response to disease and therapy
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.
N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.
Phase I Trial of ALT-803, a Novel Recombinant Interleukin-15 Complex, in Patients with Advanced Solid Tumors.
Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS. Clin Cancer Res. 2018 Jul 25. pii: clincanres.0945.2018. doi: 10.1158/1078-0432.CCR-18-0945. [Epub ahead of print] PMID: 30045932
Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.
Gorlov I, Orlow I, Ringelberg C, Hernando E, Ernstoff MS, Cheng C, Her S, Parker JS, Thompson CL, Gerstenblith MR, Berwick M, Amos C.
Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000473. [Epub ahead of print]
Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor.
Montano R, Khan N, Hou H, Seigne J, Ernstoff MS, Lewis LD, Eastman A.
Oncotarget. 2017 Jun 28;8(40):67754-67768. doi: 10.18632/oncotarget.18834. eCollection 2017 Sep 15.
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS.
J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8.